A Study of a Distress Screening and Referral Program in People With Recently Diagnosed Cancer
Part of paid clinical trials in New York, New York.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT07117461
- Status
- Recruiting
Conditions
- Solid Tumor Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- NCCN Distress Thermometer — BEHAVIORALA tool used to determine on a number scale the amount of distress for the past week
Study Details
It is recommended that cancer centers screen patients for distress and refer them to mental health services when their distress levels reach a certain level. However, many cancer centers don't have distress screening and referral programs. This study will provide valuable information about one distress screening and referral program and whether it can be helpful for a large and diverse group of cancer patients that includes both English- and Spanish-speaking patients.
Key Dates
- Start date
- Jul 22, 2025
- Status verified
- Oct 2025
- Primary completion
- Jul 22, 2026
- Completion
- Jul 22, 2026
Study Design
- Enrollment
- 50 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Participants with a New Solid Tumor DiagnosisParticipants will have a new solid tumor cancer diagnosis.
Primary Outcome Measure
Participant referral rate to mental health services [ Time Frame: 3 months ]
Central Contacts
- Devika Jutagir, PhD646-888-8361
- Francesca Gany, MD646-888-8054
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York | New York | 10065 | Devika Jutagir, PhD 646-888-8361 |
| Medisys Health Network (Data Collection Only) | Richmond Hill | New York | 11418 | Ateaya Lima, MD 718-206-6000 |
Find similar trials in New York, NY
Related Studies
- A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) ProductsEnrolling By Invitation · A2 Biotherapeutics Inc. · Gilbert, Arizona
- AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)PHASE1/PHASE2 · Recruiting · Avenzo Therapeutics, Inc. · Gilbert, Arizona
- BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)PHASE1/PHASE2 · Recruiting · Avenzo Therapeutics, Inc. · San Francisco, California
- Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid TumorsRecruiting · Washington University School of Medicine · St Louis, Missouri